New Chemical Compounds Can Precisely Target the Brain's Cannabis-Processing Enzymes | Research

The takeaway

Researchers developed a class of compounds that can selectively block either one or both of the enzymes that break down the brain's natural cannabis-like molecules, with potential applications for pain, anxiety, and depression.

Read this if you are interested in how future cannabis-based medicines might work without producing a high.

SA-57 hit only 3 targets out of the entire brain proteome

What the researchers found

The researchers investigated O-hydroxyacetamide carbamate compounds and found they could be tuned to selectively inhibit FAAH (the enzyme that breaks down anandamide) or to simultaneously inhibit both FAAH and MAGL (which breaks down 2-AG). One compound, SA-57, showed remarkable selectivity in living animals.

At doses suitable for behavioral studies (0.125 to 12.5 mg/kg), these compounds raised brain levels of natural endocannabinoids without the broad psychoactive effects of directly activating cannabinoid receptors.

Why it matters

Direct cannabinoid receptor activation (like THC) produces a wide range of psychoactive effects. By instead boosting the body's own endocannabinoids through enzyme inhibition, these compounds could potentially provide pain relief, reduce anxiety, and improve mood without the full psychotropic profile.

The numbers in context

Dose range tested: 0.125 to 12.5 mg/kg. SA-57 targeted only FAAH, MAGL, and one additional enzyme (ABHD6) out of the entire brain proteome.

How the study worked

The study used competitive and click chemistry activity-based protein profiling to assess compound selectivity in mouse brains. Researchers tested multiple doses across the range to determine in vivo activity and selectivity profiles for FAAH and MAGL inhibition.

What this study cannot tell us

This was a preclinical chemistry and pharmacology study conducted in rodents. Whether these compounds translate to safe, effective human therapeutics remains unknown. Long-term effects of sustained endocannabinoid elevation were not assessed.

How to read the evidence

Preclinical pharmacology study in rodents; no human data yet.

When this study was published

Published in 2012. FAAH and MAGL inhibitor research has continued, with some compounds entering clinical trials.

The bigger picture

This research represents a strategy shift in cannabinoid medicine: rather than adding external cannabinoids, boost the ones the brain already makes. The ability to fine-tune which endocannabinoid pathway gets amplified could lead to more targeted therapies with fewer side effects.

Questions still open

Will these compounds prove safe and effective in human trials? Can the selectivity demonstrated in rodents be maintained in human tissue? What are the long-term consequences of chronically elevated endocannabinoid levels?

Common questions

What are FAAH and MAGL?

FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase) are enzymes that break down the brain's natural endocannabinoids, anandamide and 2-AG respectively. Blocking these enzymes raises endocannabinoid levels in the brain.

How is this different from using THC?

THC directly activates cannabinoid receptors throughout the brain. These inhibitors instead boost the brain's own endocannabinoids in the specific locations where they are naturally released, which may produce more targeted effects with fewer psychoactive side effects.

Read the original research

O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.

ACS chemical neuroscience, 3(5), 418-26

View on PubMed ↗Publisher’s paper ↗

Citation

Niphakis, Micah J; Johnson, Douglas S; Ballard, T Eric; Stiff, Cory; Cravatt, Benjamin F. (2012). O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.. ACS chemical neuroscience, 3(5), 418-26. https://doi.org/10.1021/cn200089j